CTI BioPharma Corp. (NASDAQ:CTIC)

CAPS Rating: 1 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Results 1 - 20 of 55 : 1 2 3 Next »

Recs

0
Member Avatar SmartAce (99.89) Submitted: 2/22/2016 2:13:07 PM : Underperform Start Price: $0.68 CTIC Score: +40.40

The only place worth being.

Recs

0
Member Avatar zzlangerhans (99.79) Submitted: 2/22/2016 11:17:03 AM : Underperform Start Price: $0.51 CTIC Score: +18.93

I have to admit I got sucked into Cell Therapeutics' transient success with pacritinib and green thumbed them about a year ago, ruining my perfect record on the stock. Fortunately I never followed up that green thumb with a real money bet. As it turned out, pacritinib is going down the toilet along with all of Cell Therapeutics' other programs over the years. A red thumb is still the right bet for this stock no matter how much it looks like they've finally developed a legitimate drug.

This month the company withdrew their NDA for pacritinib thanks to an FDA full clinical hold regarding a detrimental effect of pacritinib on overall survival in both of the two phase III trials. That's a polite way of saying the drug kills people. Not good. Given how bad this looks and Cell Therapeutics' long history of failure, I think we can discard pacritinib from the company's value equation.

What's left? The new lead drug is tosedostat. In December management reported a complete response rate of 49% at an interim analysis of the phase II IST of tosedostat in AML. Tosedostat is also being tested for AML in a "Pick-A-Winner" program developed by the NCRI of the UK. Management is planning discussions regarding registrational trials of tosedostat with regulators in the US and UK later this year. Paclitaxel analogue Opaxio wasn't mentioned in the last earnings PR, although a phase III trial as maintenance therapy in ovarian cancer is supposedly in progress. Pixuvri is showing weak and static revenues, barely over 1M in the last quarter reported. This drug seems to be going nowhere commercially.

Cell Therapeutics has 128M in cash thanks to a series of vulture financings conducted in late 2015. These financings involved the creation of preferred stock equivalent to 90M of common, so there is at least 60M of hidden market cap in addition to the 190M cap based on the outstanding common. There's probably plenty of other preferred stock and options still out there that I haven't kept track of adding to the hidden cap. There's also 52M in long-term debt and a quarterly burn over 20M.

For some reason Cell Therapeutics isn't trading under cash despite the fact that several bios with better pedigrees and prospects are doing exactly that. If we subtract the debt and two quarters of burn from the cash that leaves us with 36M net as of the end of March 2016. Meanwhile, the market cap including preferred stock is over 250M with no positive catalysts apparent on the near term horizon. Cell Therapeutics may be catching a little air for now, but the street has proven to be a harsh mistress for biotech of late. I really don't see this ending well.

Recs

0
Member Avatar TSIF (99.95) Submitted: 2/17/2016 12:58:13 PM : Underperform Start Price: $0.50 CTIC Score: +18.27

Sometimes these sub $0.50 can spike from news that leaks...but this is extremely rare...
The more likely reasons is oscillation....someone pushes, shorts cover, speculators enter, day traders enter, previous bag holders who have smartened up sell, those that believe they were right, just early, remain bag holders when the oscillation fizzles.

Only lost $25M in the fourth quarter, or $119M for the year...

Pulled in $115M from issues in October and December, before announcing the FDA had placed pacritinib's IND on a full clinical hold. Other pipeline draining cash, some partners/milestones.
$128M in cash reserves. Slightly under Market Cap...

I'd expect a reverse split about any time.

Target, excluding a R/S.... about $0.35 if that...

Recs

0
Member Avatar 78taxs (< 20) Submitted: 5/28/2015 2:00:01 PM : Outperform Start Price: $1.86 CTIC Score: -72.80

Cancer. With less rad.

Recs

1
Member Avatar afrisque61 (< 20) Submitted: 2/15/2015 4:33:38 PM : Outperform Start Price: $2.21 CTIC Score: -77.81

Once a high-flyer, potentially poised for growth due to new product development.

Recs

2
Member Avatar kyawam (< 20) Submitted: 1/15/2014 12:52:43 AM : Outperform Start Price: $3.04 CTIC Score: -96.75

The company has been developing the drugs in their niche area for a while, having got partnership with Baxter to develop and commercialize for one of their drugs is a form of certification that the drugs is credible and have commercial potential. Some more recent unfreezing of FDA to continue one of their trial is also another good news for investor.

Recs

0
Member Avatar Jibo999 (< 20) Submitted: 1/7/2014 4:21:43 PM : Outperform Start Price: $2.36 CTIC Score: -92.94

CTI is performing extremely well for the last few moth. The stock has lots of potential for grow.

Recs

0
Member Avatar FULAWRENCEI (36.27) Submitted: 10/8/2013 8:03:04 AM : Outperform Start Price: $1.90 CTIC Score: -99.10

Super high interest, I get a kick out of people saying the company diluted shares when in fact the company reduced the number of shares by reverse splits 4 times!

Recs

0
Member Avatar ImFive (< 20) Submitted: 10/6/2013 11:11:07 PM : Outperform Start Price: $1.69 CTIC Score: -96.18

woah oh, livin' on a prayer

Recs

0
Member Avatar rknapton (67.49) Submitted: 8/6/2013 7:26:05 PM : Underperform Start Price: $1.08 CTIC Score: +80.06

CTIC Short. Biotech. No revenues, just issues more and more stock. Reminds me of china crescent.

Recs

0
Member Avatar bIlluminati (32.20) Submitted: 7/2/2013 2:45:48 PM : Underperform Start Price: $1.00 CTIC Score: +83.35

No profits.

Recs

0
Member Avatar allstar31 (99.85) Submitted: 4/27/2013 10:11:59 PM : Underperform Start Price: $1.18 CTIC Score: +91.58

Worthless Biopharm company. Has a drug twice rejected by the FDA but was approved for European use. AVOID.

Recs

0
Member Avatar aaronleetx (< 20) Submitted: 1/8/2013 5:18:56 PM : Outperform Start Price: $1.55 CTIC Score: -111.90

I think you guys will be awsome!!!!:D

Recs

0
Member Avatar OBAMABB (< 20) Submitted: 6/26/2012 7:10:59 PM : Outperform Start Price: $2.95 CTIC Score: -139.77

Keep Bashing CTIC 65 times in 6 months means you are trying to manipulate the stock your buddies must be real short!

Recs

0
Member Avatar bobleelaw (25.35) Submitted: 6/22/2012 7:02:32 PM : Outperform Start Price: $3.10 CTIC Score: -140.93

Cell Therapeutics, Inc. (CTIC)
Is well undervalued for what it has in the pipeline. This stock will be 100+% investor return in the next 6 months. I am not sure why it is not getting the attention it should, but that is fine by me as I accumulate shares on the cheap.

Recs

0
Member Avatar liken22 (< 20) Submitted: 1/30/2012 10:59:47 AM : Outperform Start Price: $5.41 CTIC Score: -148.59

Hit the lowest cap in a long time, so I think will go up

Recs

0
Member Avatar tommywaaf (< 20) Submitted: 1/26/2012 5:14:28 PM : Outperform Start Price: $6.75 CTIC Score: -149.63

Euro possible apporval in mid feb. Could bring interest

Recs

0
Member Avatar ltgenspecific (< 20) Submitted: 6/14/2010 5:44:12 PM : Outperform Start Price: $14.94 CTIC Score: -156.15

going with the gut, something's bound to give, Pixuvri seems to be somewhat effective... risky but if it takes, it'll run

Recs

0
Member Avatar libertybrewcity (< 20) Submitted: 9/3/2009 12:59:57 AM : Outperform Start Price: $45.90 CTIC Score: -204.20

The new drug is about to go into phase 3 and the stock will explode!

Recs

3
Member Avatar dbbfool63 (23.28) Submitted: 8/27/2009 6:28:48 PM : Outperform Start Price: $47.70 CTIC Score: -196.70

Good entry point for mid to long term.

I couldn't get in until it got above a dollar to rate it although been watching since .o7/shr.

Probably could of got in lower, but lost track watching others.

Results 1 - 20 of 55 : 1 2 3 Next »

Featured Broker Partners